Core Insights - Geron Corporation is forecasting $220–240 million in revenue from RYTELO (imetelstat) and $230–240 million in operating expenses for 2026, following a recent restructuring aimed at achieving profitability [1][2] - The company is focusing on U.S. commercialization, international expansion, and advancing its Phase 3 IMpactMF trial, with an emphasis on building clinical support for RYTELO [2][5] - A restructuring initiative is underway, which includes a workforce reduction of nearly one-third, expected to incur $18 million in restructuring charges [3][4] Financial Outlook - Geron anticipates stronger growth in the second half of 2026 as it increases outreach to physicians and patients [1] - The company has amended its loan agreement with Pharmakon Advisors, securing access to up to $125 million through July 2026 [2] Strategic Focus - The primary objectives include driving RYTELO commercial growth in the U.S., exploring international opportunities, and advancing the Phase 3 IMpactMF trial [5][6] - The restructuring is expected to significantly impact operating expenses and better position the company to meet patient needs [5]

2026 RYTELO® (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line growth and streamlined operations to support path toward building a sustainable hematology company FOSTER CITY, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, aiming to change lives by changing the course of blood cancer, today announced 2026 financi ...

Core Insights - Geron Corporation has announced a strategic restructuring plan aimed at long-term value creation for patients and shareholders while improving financial discipline [2][3] - The restructuring is expected to lead to a one-third reduction in the current workforce of approximately 260 employees, with significant savings anticipated in operating expenses for 2026 [3] Group 1: Restructuring Plan - The restructuring plan is designed to streamline the organizational structure and advance the company's strategy [3] - Initial projected full year 2026 operating expenses are expected to be lower than those projected for 2025, with savings beginning in the first quarter of 2026 [3] - The restructuring will incur cash-based expenses, with further details to be provided in a Current Report on Form 8-K [3] Group 2: Business Focus - The company remains focused on driving the commercial growth of RYTELO in the U.S. and exploring opportunities for its availability outside the U.S. [3] - Geron is continuing to advance its Phase 3 IMpactMF trial, which is critical for the development of its lead product, RYTELO [3][4] - RYTELO (imetelstat) is a first-in-class telomerase inhibitor approved for treating certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) [4]

Core Insights - Geron Corporation presented new data at the ASH 2025 Annual Meeting, reinforcing the potential of RYTELO (imetelstat) as a treatment for lower-risk myelodysplastic syndromes (LR-MDS) and myelofibrosis (MF) [1][2][4] Group 1: Clinical Efficacy of Imetelstat - Pooled analyses from the IMerge trial suggest that early treatment-emergent cytopenias may correlate with significant clinical outcomes, including hemoglobin increases and transfusion independence in LR-MDS patients [2][4][6] - The data indicate that patients experiencing ≥75% reductions in neutrophils or ≥50% reductions in platelets during the first two cycles of treatment had greater maximum hemoglobin increases compared to those without such reductions [5][6] - Long-term follow-up from the IMerge trial shows favorable trends in overall survival (OS) and progression-free survival (PFS) for imetelstat-treated patients compared to placebo, with a median follow-up of 45 months [7][8][9] Group 2: Mechanism of Action and Biological Insights - Imetelstat's mechanism involves telomerase inhibition, which is crucial for the uncontrolled cell division seen in LR-MDS, and the treatment has shown potential disease-modifying properties [19][20] - The correlation between early blood count changes and later improvements in hemoglobin provides valuable insights for clinicians regarding the treatment's biological effects [3][6] Group 3: Additional Studies and Future Directions - Ongoing studies, including the IMproveMF trial, are evaluating the safety and efficacy of imetelstat in combination with ruxolitinib for patients with intermediate-2 or high-risk myelofibrosis [13][14] - Preliminary results from the IMpress study indicate that imetelstat has a manageable safety profile in advanced myelodysplastic neoplasms or acute myeloid leukemia patients who are refractory to prior treatments [15][16][17]

Core Insights - Geron Corporation is experiencing a bullish sentiment on Wall Street due to its plans to enhance the commercialization of Rytelo, a medication for anemia [2][3] - The company aims to reposition Rytelo for earlier treatment lines, particularly as a second-line therapy, and will implement strategies to increase physician awareness [2][3] - Despite stagnating sales of approximately $50 million in 2025, Geron is optimistic about significant growth in 2026 [2] Company Overview - Geron Corporation is a biopharmaceutical company focused on developing treatments for blood cancers, specifically myeloid hematologic malignancies [4] - Its primary product, Rytelo (imetelstat), is an approved telomerase inhibitor for certain patients with lower-risk myelodysplastic syndromes, with ongoing research for its application in other blood cancers [4] Analyst Ratings - Needham analyst Gil Blum has reiterated a Buy rating for Geron with a price target of $4 [3] - Leerink Partners has maintained an Outperform rating but reduced the price target from $3 to $2, while expecting the company to take necessary steps to improve Rytelo's performance [3]

Core Insights - Geron Corporation has announced significant executive transitions to align its leadership with strategic priorities, including the appointment of Ahmed ElNawawi as the new Chief Commercial Officer [1][2][3] Leadership Changes - Andrew Grethlein, the current Chief Operating Officer, will transition to a consulting role effective October 15, 2025, after serving since January 2019 [1] - Jim Ziegler, the current Chief Commercial Officer, will also depart on October 15, 2025, to pursue other interests [1] - Ahmed ElNawawi will take over as Chief Commercial Officer on October 20, 2025, focusing on driving growth and maximizing the potential of RYTELO [1][2] New Executive Appointments - Three additional executives have been appointed: - Shanthakumar Tyavanagimatt as Senior Vice President, Chief Technical Officer, bringing over 25 years of experience in drug development and technical operations [2][5] - Dawn Schottlandt as Senior Vice President, Investor Relations and Corporate Affairs, with over 20 years in investor relations within the life sciences industry [2][8] - Bryan Ridgell as Senior Vice President, Portfolio and Project Management and Chief of Staff, with extensive experience in program and portfolio management [2][8] Strategic Focus - The new leadership team is expected to enhance Geron's capabilities in commercial, operational, and development areas, particularly in expanding the reach and impact of RYTELO [3][4] - ElNawawi aims to deepen engagement and deliver operational excellence across the business, building on the existing foundation [4] Company Overview - Geron Corporation is a commercial-stage biopharmaceutical company focused on changing the course of blood cancer, with its first-in-class telomerase inhibitor RYTELO approved for certain adult patients with lower-risk myelodysplastic syndromes [6]